US clears first ‘living drug’ for tough childhood leukemia – Carlisle Sentinel
The Pharma Letter (registration) |
US clears first ‘living drug’ for tough childhood leukemia
Carlisle Sentinel The CAR–T cell treatment developed by Novartis and the University of Pennsylvania is the first type of gene therapy to hit the U.S. market — and one in a powerful but expensive wave of custom-made “living drugs” being tested against blood cancers and … Today’s miracle is tomorrow’s also-ran in hottest cancer fieldLaredo Morning Times Following IBMTR model may make CAR–T therapies affordable, says oncologist and data specialistThe Pharma Letter (registration) Landmark Approval of Kymriah Won, Novartis’ Next Test Is Scaling CAR–T ManufacturingManaged Care magazine http://theliberal.ie/ (press release) (blog) all 15 news articles » |
The Pharma Letter (registration) |
FDA approves first ‘living drug’ for tough childhood leukemia
KTRK-TV “This is a brand new way of treating cancer,” said Dr. Stephan Grupp of Children’s Hospital of Philadelphia, who treated the first child with CAR–T cell therapy – a girl who’d been near death but now is cancer-free for five years and counting. “That’s … US clears first ‘living drug’ for tough childhood leukemiaCarlisle Sentinel Following IBMTR model may make CAR–T therapies affordable, says oncologist and data specialistThe Pharma Letter (registration) Today’s miracle is tomorrow’s also-ran in hottest cancer fieldLaredo Morning Times The Hindu –BioWorld Online –pharmabiz.com all 23 news articles » |
Cancer Research UK (blog) |
News digest – CAR T cells, nanomachines, vaping in teens and… selfies diagnosing cancer?
Cancer Research UK (blog) A medical milestone was reached this week as the US approved CAR T cell therapy for a small number of children and young adults with a particular type of leukaemia. The go-ahead for the new treatment, which engineers a patient’s own immune cells to … |
|
Manufacturing Standards Key to Advancing Cellular and Gene Therapies
Pharmaceutical Technology Magazine Similar issues have been discussed related to applications for Kite Pharma’s therapy for aggressive non-Hodgkin lymphoma and Spark Therapeutics’ new gene therapy to treat a rare condition causing blindness, which are moving through the FDA approval … |
Business Weekly |
Cambridge Enterprise and Qkine to drive stem cell and regenerative medicine research
Business Weekly The newly-licensed methodology, which was developed by one of the company’s founders Dr Marko Hyvönen, will be used to manufacture proteins utilised for control of stem cell growth and differentiation. Growth factors are proteins that transmit signals … |